Alzheimer's dementia (AD) is the most common type of dementia. In addition to the cognitive and functional disturbances that happen as the disease progresses, other psychological disturbances may manifest. Depression, insomnia, anxiety, and psychosis are among several psychological conditions which can occur concomitantly with AD. These changes can result in decreased quality of life for both patients and caregivers, increase caregiver burden, and impact the decision to place a patient with AD into a long-term care facility. An evidence-based review of the literature was performed to ascertain if a specific recommendation for pharmacotherapy can be made based on current research in this specific patient population.
Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA.2006; 295:2148-2157.
2.
Sink KM, Holden KF, Yaffe K.Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA.2005;293:596-608.
3.
Trinh NH, Hoblyn J., Mohanty S., Yaffe K.Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease. JAMA.2003;289:210-216.
4.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Revision. Washington, DC: American Psychiatric Association, 2000.
5.
McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EMClinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 ;34:939-944.
6.
Blessed G., Tomlinson BE, Roth M.The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry . 1968;114:797-811.
7.
Grundke-Iqbal I., Iqbal K., Tung YC, Quinlan M., Wisniewski HM, Binder LIAbnormal phosphorylation of the micro-tubule-associated protein tau in Alzheimer's cytoskeletal pathology . Proc Natl Acad Sci.1986;83:4913-4917.
8.
Nukina N., Ihara Y.One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem (Tokyo). 1986 ;99:1541-1544.
9.
Terry, AV Jr, Buccafusco JJThe cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther.2003;306:821-827.
10.
Aerosa SA, Sherriff F., McShane R.Memantine for dementia. Cochrane Database Syst Rev.2005;3:CD003154.
11.
Tacrine. In: Lacy CF, Armstrong LL, Goldman MP , et al, eds. Lexi-Comp's Drug Information Handbook. Hudson, Oh: Lexi-Comp;2006.
12.
Donepezil In: Lacy CF, Armstrong LL, Goldman MP , et al, eds. Lexi-Comp's Drug Information Handbook. Hudson, Oh: Lexi-Comp;2006.
13.
Rivastigmine. In: Lacy CF, Armstrong LL, Goldman MP, et al, eds. Lexi-Comp's Drug Information Handbook . Hudson, Oh: Lexi-Comp;2006.
14.
Galantamine. In: Lacy CF, Armstrong LL, Goldman MP , et al, eds. Lexi-Comp's Drug Information Handbook. Hudson, Oh: Lexi-Comp;2006.
15.
Memantine In: Lacy CF, Armstrong LL, Goldman MP , et al, eds. Lexi-Comp's Drug Information Handbook. Hudson, Oh: Lexi-Comp;2006.
16.
Cummings JLAlzheimer's disease. N Engl J Med.2004;351:56-67.
17.
Rogers SL, Farlow MR, Doody RS, Mohs R., Friedhoff LT, Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology . 1998;50:136-145.
18.
Corey-Bloom J., Anand R., Veach J., for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol.1998;1:55-65.
19.
Raskind MA, Peskind ER, Wessel T., Yuan W., and the GalantamineUSA-1 Study Group. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-2268.
20.
Tariot PN, Solomon PR, Morris JC, et al, for the Galantamine USA-Study Group. A 5-month randomized, placebo-controlled trial of galantamine in AD. Neurology.2000 ;54:2269-2276.
21.
Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt HP, van den Bussche H.Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ.2005;331:321-327.
22.
Doraiswamy PM, Kaiser L., Bieber F., Garman RLThe Alzheimer's disease assessment scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord. 2001 ;15:174-183.
23.
AD2000 Collaborative Group.Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet. 2004 ;363:2105-2115.
24.
Pirttila T. , Wilcock G., Truyen L., Damaraju CVLong-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol.2004;11:734-741.
25.
Lyketsos CG , Reichman WE, Kershaw P., Zhu Y.Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry . 2004;12:473-482.
26.
Farlow M., Anand R., Messina J., Hartman R., Veach J.A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur J Neurol.2000;44:236-241.
27.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S., Gergel I for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA.2004;291:317-324.
28.
Peskind ER, Potkin SG, Pomara N., et al for the Memantine MEM-MD-10 Study Group. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized controlled trial . Am J Geriatr Psychiatry.2006;14:704-715.
29.
Reisberg B. , Doody R., Stoffler A., Schmitt F., Ferris S., Mobius HJfor the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med.2003;348:1333-1341.
30.
Reisberg B. , Doody R., Stoffler A., Schmitt F., Ferris S., Mobius HJA 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol.2006; 63:49-54.
31.
Guideline Watch. Practice guidelines for the treatment of patients with Alzheimer's Disease and other dementias of late life. Available at: http://www.psych.org/psych_pract/treatg/pg/Alzheimers.watch.pdf . Accessed March 15, 2007.
32.
Reifler BV, Larson E., Hanley R.Coexistence of cognitive impairment and depression in geriatric outpatients . Am J Psychiatry.1982;139:623-626.
33.
Reifler BV, Larson E., Teri L., et al. Dementia of Alzheimer's type and depression. J Am Geriatr Soc.1986;34:855-859.
34.
Rovner BW, Broadhead J., Specer M., et al. Depression and Alzheimer's disease. Am J Psychiatry.1989;146:350-353.
35.
Raskind MAGeriatric Psychopharmacology: Management of late-life depression and the non-cognitive behavioral disturbances of Alzheimer's disease. Psychiatr Clin North Am.1993;16:815-826.
36.
Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:125-128.
37.
Lawler BA, Johannessen DJ, Aupperle PM, et al. Neurobiology of behavioral symptoms in Alzheimer's disease. Presented at: the American Psychiatric Association, 144th Annual Meeting; May 1991; New Orleans, La.
38.
Petracca G., Teson A., Chemerinski E., Leiguarda R., Starkstein SEA double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatr Clin Neurosci.1996;8:270-275.
39.
Reifler BV, Teri L., Raskind MA, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry.1989;146:45-49.
40.
Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Diaz, E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics. 1997;38: 246-252.
41.
Lyketsos CG , DelCampo L., Steinberg M., et al. Treating depression in Alzheimer's disease. Efficacy and safety of sertraline therapy and the benefits of depression reduction: The DIADS. Arch Gen Psychiatry . 2003;60:737-746.
42.
Martin BK, Frangakis CE, Rosenberg PB, et al. Design of depression in Alzheimer's disease study-2 . Am J Geriatr Psychiatry.2006;14:920-930.
43.
Magai C., Kennedy G., Cohen CI, Gomberg D.A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry. 2000;8:66-74.
44.
Petracca GM , Chemerinski E., Starkstein SEA double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr2001;13:233-240.
45.
Raji MA, Brady SRMirtazapine for treatment of depression and comorbidities in Alzheimer's disease . Ann Pharmacother.2001;35:1024-1027.
46.
Fick DM, Cooper JW, Wade WE, Waller JL, Maclean R., Beers MHUpdating the Beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med.2003 ;163: 2716-2724.
47.
Swearer J., Drachman D., O'Donnell B., Mitchell A.Troublesome and disruptive behaviors in dementia. J Am Geriatr Soc.1988; 36:784-790.
48.
Skene DJ, Swaab DFMelatonin rhythmicity: effect of age and Alzheimer's disease. Exper Gerontol.2003;38:199-206.
49.
McCurry SM, Reynolds CF, Ancoli-Israel S., et al. Treatment of sleep disturbance in Alzheimer's disease. Sleep Med Rev.2000;4:603-628.
50.
Mishima K., Tozawa T., Satoh K., Matsumoto Y., Hishikawa Y., Okawa M.Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry.1999;45:417-421.
51.
Liu RY, Zhou JN, van Heerikhuize J., Hofman MA, Swaab DFDecreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab.1999;84: 323-327.
52.
Uchida K., Okamoto N., Ohara K., Morita Y.Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res.1996;717:154-159.
53.
McCarten JR , Kovera C., Maddox MK, Cleary JPTriazolam in Alzheimer's disease: pilot study on sleep and memory effects. Pharmacol Biochem Behav. 1995;52:447-452.
54.
Singer C., Tractenberg RE, Kaye J., et al for the Alzheimer's Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003;26:893-901.
55.
Serfaty M., Kennell-Webb S., Warner J., Blizard R., Raven P.Double blind randomized placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry.2002;17:1120-1127.
56.
Treatment of subjects with mild to moderate Alzheimer's disease and sleep disturbance with Rozerem. Clinicaltrials.gov identifier : NCT00325728. Available at: http://www.clinicaltrials.gov/ct/show/NCT00325728?order=1. Accessed March 12, 2007.
57.
Jeste DV, Meeks TW, Kim DS, Zubenko GSResearch agenda for DSM-V: diagnostic categories and criteria for neuropsychiatric syndromes in dementia. J Geriatr Psychiatry Neurol.2006;19:160-171.
58.
Devanand DP , Marder K., Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry.1998;155:1512-1520.
59.
Brodaty H., Low LFAggression in the elderly. J Clin Psychiatry.2003;64(Suppl 4):36-43.
60.
Lesser JM, Hughes SVPsychosis, agitation and disinhibition in Alzheimer's disease: definitions and treatment options. Geriatrics.2006;61:14-20.
61.
Lonergan E. , Luxenberg J., Colford J.Haloperidol for agitation in dementia. Cochrane Database Syst Rev.2001;4:CD002852.
62.
Ballard C., Waite J.The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev.2006;1:CD003476.
63.
Rabinowitz J, DeDeyn PP, Brodaty H, Greenspan A, Davidson M. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. J Clin Psychiatry.2004;65:1329-1334.
64.
Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch Gen Psychiatry. 2000; 57:968-976.
65.
Fujikawa T. , Takahashi T., Kinoshita A., et al. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type . Neuropsychobiology.2004 ;49:201-204.
66.
Ballard C., Margallo-Lana M., Juszczak E., et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomized double blind placebo controlled trial. BMJ.2005;330:874.
67.
Porsteinsson AP, Tariot PN, Erb R., et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry . 2001;9:58-66.
68.
Porsteinsson AP, Tariot PN, Erb R., Gaile S.An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry . 1997;5:344-351.
69.
Pollock BG, Mulsant BH, Rosen J., et al. Comparison of citalopram, perphenazine and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry.2002;159:460-465.
70.
Scharre DW, Davis RA, Warner JL, Chang S., Beversdorf DQA pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer's disease. Am J Geriatr Psychiatry . 2003;11:687-691.
71.
Sultzer DL, Gray A., Gunay I., et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry . 1997; 60-69.
72.
Cummings JL, Schneider L., Tariot PN, Kershaw PR, Weiying Y.Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry.2004;161:532-538.
73.
Weiner MF, Martin-Cook K, Foster BM, Saine K., Fontaine CS, Svetlik DAEffects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry.2000;61:487-492.
74.
Rosler M., Retz W, Retz-Junginger, Dennler HJ. Effects of two-year treatment with the cholinestease inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol.1998;11:211-216.
75.
Cummings JL, Schneider E., Tariot PN, Graham SM, and the MemantineMEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology . 2006;67:57-63.
76.
Sleeper RBAntipsychotic dose-sparing effect with addition of memantine. Ann Pharmacother.2005;39:1573-1576.
77.
Mega MS, Cummings JL, Fiorello T., Gornbein J.The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46:130-135.
78.
Hirono N., Mori E., Yasuda M., et al. Factors associated with psychotic symptoms in Alzheimer's disease . J Neurol Neurosug Psychiatry.1998;64:648-652.
79.
Rosen J., Zubenko GSEmergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatr. 1991 ;29:224-232.
80.
Jeste DV, Finkel SIPsychosis of Ahzimer's disease and related dementias. Am J Geriatr Psychiatry.2000;8:29-33.
81.
Burn A., Jacoby R., Levy R.Psychiatric phenomena in Alzheimer's disease, I: disorders of thought content . Br J Psychiatry. 1990;157:72-76.
82.
Bassiony MM , Warren A., Rosenblatt A., et al. The relationship between delusions and depression in Alzheimer's disease. Int J Geriatr Psychiatry . 2002;17:549-556.
83.
Devanand DP , Jacobs DM, Tang M., et al. The course of psychopathologic features in mild to moderate Alzheimer's disease. Arch Gen Psychiatry . 1997;54:257-263.
84.
Reisberg B. , Franssen E., Sclan SG, Kluger A., Ferris SHStage-specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer's disease: a study of 120 patients using the BEHAVE-AD. Bull Clin Neurosci.1989 ;54: 95-112.
85.
Scarmeas N. , Brandt J., Albert M., et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol.2005;62:1601-1608.
86.
Shigenobu K. , Ikeda M., Fukuhara R., et al. Reducing the burden of caring for Alzheimer's disease through the amelioration of `delusions of theft' by drug therapy. Int J Geriatr Psychiatry. 2002;17:211-217.
87.
Mintzer J., Greenspan A., Caers I., et al. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry . 2006;14: 280-291.
88.
Katz IR, Jeste DV, Mintzer JE, et al, for the Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry.1999;60: 107-115.
89.
Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia . Am J Geriatr Psychiatry. 2005;13:722-730.
90.
Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia . Int J Geriatr Psychiatry. 2001;16:S62-S70.
91.
De Deyn PP, Carrasco, MM, Deberdt W., et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry.2004;19:115-126.
92.
Tariot PN, Schneider L., Katz IR, et al. Quetiapine treatment of pyschosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14:767-776.
93.
De Deyn P., Jeste DV, Swanink R., et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease. J Clin Psychopharmacol.2005;25:463-467.
94.
Edwards K., Koumaras B., Chen M., Gunay I., Mirski D., and the RivastigminNursing Home Study Team. Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer's disease. Clin Drug Invest.2005;25:507-515.
95.
Cummings JL , McRae T., Zhang R.Effects of donepezil on Neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14:605-612.
96.
Schneider LD , Dagerman KS, Insel P.Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA.2005;294:1934-1943.
97.
Wang PS, Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med.2005 ;353:2335-2341.
98.
Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry2004;65(Suppl 7):4-18.
99.
Fda PublicHealth Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. Available at: http://www.fda.gove/cder/drug/advisory/antipsychotics.htm. Accessed March 15, 2007.
100.
Gill SS, Rochon PA, Herrmann N., et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ.2005 ;330:445.
101.
Schneider LS, Tariot PN, Dagerman KS, et al for the CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med.2006;355:1525-1538.
102.
Alexopoulos GS, Streim J., Carpenter D., Docherty JPUsing antipsychotics agents in older patients . J Clin Psychiatry.2004;65(Suppl 2):1-105.
103.
Lee PE, Gill SS, Freedman M., Bronskill SE, Hillmer MP, Rochon PAAtypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ.2004;329:75-79.
104.
Smith A.Behavioral problems in dementia: strategies for pharmacologic and nonpharmacologic management. Postgrad Med.2004;115:47-56.
105.
Reisberg B. , Auer SR, Monteiro IMBehavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr. 1996;8(Suppl 3):301-308.
106.
Hamilton M.A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
107.
Montgomery SA, Asberg M.A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
108.
Folstein MF, Folstein SE, McHugh PR “ Mini-Mental State.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res.1975;12:189-198.
109.
Cummings JL, Mega M., Gray K., Rosenberg-Thompson S., Carusi DA, Gornbein J.The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology.1994;44:2308-2314.
110.
Wood S., Cummings JL, Hsu M-A., et al. The use of the Neuropsychiatric inventory in nursing home residents . Am J Geriatr Psychiatry. 2000;8:75-83.
